ライフサイエンスコーパス: spleen tyrosine kinase

1 breast tumor or metastasis suppressor, SYK (spleen tyrosine kinase).

2 bulin-E crosslinking, it did not require the spleen tyrosine kinase.

3 hways that involved the mannose receptor and spleen tyrosine kinase.

4 (GS-9973) is an oral, selective inhibitor of spleen tyrosine kinase.

5 ing protein 9 (CARD9) disturb the subsequent spleen tyrosine kinase 2-CARD9/BCL10/MALT1-driven signal

6 n an increase in tyrosine phosphorylation of spleen tyrosine kinase, a hallmark feature of the Dectin

7 mediator release, as well as Lyn kinase and spleen tyrosine kinase activation and signaling through

8 Dectin-1-mediated spleen tyrosine kinase activation is required for TLR9 t

9 s and controls phagosomal maturation through spleen tyrosine kinase activation.

10 ositol (4,5)-bisphosphate wave, and requires spleen tyrosine kinase activity.

11 The C-type lectin receptor-Syk (spleen tyrosine kinase) adaptor CARD9 facilitates protec

12 n of proximal BCR signaling, at the level of spleen tyrosine kinase and BTK, and augmented PYK2-depen

13 n Dectin-1 pathway components phosphorylated spleen tyrosine kinase and caspase recruitment domain-co

14 compromised E-selectin-induced activation of spleen tyrosine kinase and cell adhesion to intercellula

15 ind to monocyte FcgammaRIIA, which activates spleen tyrosine kinase and leads to the generation of ti

16 activated VLA-4 adhesion via phosphorylated spleen tyrosine kinase and paxillin within focal adhesio

17 es the B-cell receptor (BCR)-related kinases spleen tyrosine kinase and phosphatidylinositol 3-kinase

18 differentiated osteoclasts are dependent on spleen tyrosine kinase and phospholipase Cgamma2 phospho

19 is in turn activates the Src family kinases, spleen tyrosine kinase and PLCgamma2, and platelet integ

20 Both the spleen tyrosine kinase and Raf-1 pathways were involved

21 ited upregulated tyrosine phosphorylation of spleen tyrosine kinase and several other signal transduc

22 usly reported in platelets, to phosphorylate spleen tyrosine kinase and thus increased Ca2+ influx, p

23 eased ITAM signaling based on p-Syk (phospho-spleen tyrosine kinase) and p-PLCgamma2 (phospho-phospho

24 atalytic interaction between the kinase Syk (spleen tyrosine kinase) and the substrate PLCgamma2 to e

25 eased expression of the Fc epsilon receptor, spleen tyrosine kinase, and Bruton's tyrosine kinase, pl

26 ing the high-affinity IgE receptor subunits, spleen tyrosine kinase, and phospholipase C), production

27 eptor, differentially activate NF-kappaB and spleen tyrosine kinase, and stimulate the production of

28 ity biotinylation assays, we identified SYK (spleen tyrosine kinase) as a kinase involved in DEPTOR T

29 ession of several BCR kinases including LYN, spleen tyrosine kinase, Bruton tyrosine kinase and AKT.

30 kinase inhibitors that target BCR signaling (spleen tyrosine kinase, Bruton tyrosine kinase, PI3Kdelt

31 ting of the B-cell receptor tyrosine kinases spleen tyrosine kinase, Bruton's tyrosine kinase, and ph

32 Several spleen tyrosine kinase-coupled C-type lectin receptors (

33 emerged that Dectin-1 is one of a number of spleen tyrosine kinase-coupled C-type lectin receptors t

34 ing reactive oxygen species, thus preventing spleen tyrosine kinase dephosphorylation and perpetuatin

35 Spleen tyrosine kinase expression was found in human and

36 ispectral immunofluorescence, phosphorylated-spleen tyrosine kinase expression was localized to CD163

37 rthermore, treatment of lymphocytes with the spleen tyrosine kinase family inhibitor piceatannol redu

38 f TULA-2 resulted in hyperphosphorylation of spleen tyrosine kinase following FcgammaRIIA activation

39 which after phosphorylation by SFKs recruit spleen tyrosine kinase for further signal propagation.

40 Inhibition of spleen tyrosine kinase has attracted much attention as a

41 Inhibition of spleen tyrosine kinase has attracted much attention as a

42 arious surface molecules, phosphorylation of spleen tyrosine kinase, induction of cytokines, and hist

43 Spleen tyrosine kinase inhibition directly attenuates ai

44 with phosphatidylinositol 3-kinase delta and spleen tyrosine kinase inhibition, this phase 2 study ev

45 The Janus kinase/spleen tyrosine kinase inhibitor ASN002 significantly su

46 Fostamatinib is a spleen tyrosine kinase inhibitor recently approved for t

47 Fostamatinib is a novel spleen tyrosine kinase inhibitor that we hypothesize wil

48 Fostamatinib, a spleen tyrosine kinase inhibitor, has been reported to i

49 ion of albumin nanoparticles loaded with the spleen tyrosine kinase inhibitor, piceatannol, which blo

50 ivity to entospletinib, a recently developed spleen tyrosine kinase inhibitor.

51 imal B-cell receptor signaling pathway (e.g. spleen tyrosine kinase inhibitors and Bruton's tyrosine

52 Similarly to p38 inhibitors, current spleen tyrosine kinase inhibitors have not fulfilled the

53 identification of three series of selective spleen tyrosine kinase inhibitors that support our hypot

54 ture-guided optimization of pyridazine amide spleen tyrosine kinase inhibitors.

55 shown to result in an IL-2-inducible kinase-spleen tyrosine kinase (ITK-Syk) fusion transcript.

56 The inducible T cell kinase-spleen tyrosine kinase (ITK-SYK) oncogene consists of th

57 ession, CD203c expression, and intracellular spleen tyrosine kinase levels.

58 not PIP5K-alpha is transiently activated by spleen tyrosine kinase-mediated phosphorylation.

59 ucing peroxisome stress and attenuating SYK (spleen tyrosine kinase)-mTOR (mammalian target of rapamy

60 The activation of NLRP3 by heme required spleen tyrosine kinase, NADPH oxidase-2, mitochondrial r

61 many cytoplasmic signaling molecules such as spleen tyrosine kinase, other kinases like Bruton's tyro

62 The spleen tyrosine kinase pathway is implicated in these fu

63 suppressive cytokine IL-10 via the MyD88 and spleen tyrosine kinase pathways.

64 n used in clinical trials (eg, inhibitors of spleen tyrosine kinase, phosphatidylinositol 3-kinase, B

65 ivation via the SFK (Src family kinase)-Syk (spleen tyrosine kinase)-PLCgamma2 (phospholipase Cgamma2

66 ays validated GSK986310C as a candidate SYK (spleen tyrosine kinase) probe and X-ray crystallography

67 ton's tyrosine kinase (pBtk), phosphorylated Spleen tyrosine kinase (pSyk), and nuclear receptor Nur7

68 of Bruton's tyrosine kinase, PI3Kdelta, and spleen tyrosine kinase) represent a significant therapeu

69 ng pathway that is dependent on FcRgamma and spleen tyrosine kinase, resulting in downregulation of i

70 molecular patterns, heme training depends on spleen tyrosine kinase signal transduction pathway actin

71 sed IgE-induced phospho-intermediates in the spleen tyrosine kinase signaling pathway.

72 002 is an oral inhibitor of the Janus kinase/spleen tyrosine kinase signaling pathways, targeting sev

73 in orchestrating type 2 responses linked to spleen tyrosine kinase signaling.

74 roles in coordinating the signaling through spleen tyrosine kinase, Src family kinases, phosphatidyl

75 hly selective pharmacologic inhibitor of the spleen tyrosine kinase Syk [PRT060318; 2-((1R,2S)-2-amin

76 r differential molecular associations of the spleen tyrosine kinase Syk that preferentially binds to

77 grin, the Src family tyrosine kinase FGR and spleen tyrosine kinase SYK.

78 results were obtained with mice lacking the spleen-tyrosine kinase Syk in platelets, an essential co

79 ROS generation and spleen tyrosine kinase (Syk) activation induced by heme

80 Spleen tyrosine kinase (Syk) activation is a key interme

81 er, in macrophages, IL-17RA was required for spleen tyrosine kinase (Syk) activation upon fungal-indu

82 The results show that spleen tyrosine kinase (Syk) activation, an early step i

83 inescence detection to the direct sensing of spleen tyrosine kinase (Syk) activity and inhibition usi

84 Antibody-mediated TREM2 stimulation enhanced spleen tyrosine kinase (SYK) activity and uptake of Stap

85 from human basophils and mast cells requires spleen tyrosine kinase (SYK) activity, but SYK expressio

86 BCR signaling activates spleen tyrosine kinase (SYK) and downstream pathways inc

87 ovarian cancers identified hyperactivity of spleen tyrosine kinase (SYK) and EGFR, which mutually ph

88 -CD14 selectively inhibits TLR4 endocytosis, spleen tyrosine kinase (Syk) and IRF3 phosphorylation, a

89 lex led to the recruitment and activation of spleen tyrosine kinase (Syk) and phosphatidylinositol-4,

90 /carboplatin treatment have higher levels of spleen tyrosine kinase (SYK) and phospho-SYK.

91 vealed an increased basal phosphorylation of spleen tyrosine kinase (SYK) and phospholipase Cgamma2.

92 uction is strongly impaired by inhibitors of spleen tyrosine kinase (Syk) and PI3K.

93 ibition of SLE T cell activation by blocking spleen tyrosine kinase (Syk) and SLE T cell migration by

94 was necessary to sustain phosphorylation of spleen tyrosine kinase (SYK) and the B-cell linker prote

95 re upstream protein tyrosine kinases such as spleen tyrosine kinase (SyK) and the JAK family of kinas

96 lation of this tyrosine initiates binding of spleen tyrosine kinase (Syk) and triggers further downst

97 was abolished by pharmacological blockade of spleen tyrosine kinase (Syk) and was absent in Syk(-/-)

98 The spleen tyrosine kinase (Syk) and zeta-associated protein

99 Shinde and colleagues identified spleen tyrosine kinase (SYK) as a critical mediator of M

100 vidence for a previously unknown function of spleen tyrosine kinase (SYK) as a partner and posttransl

101 Using a proteomics approach, we identified spleen tyrosine kinase (Syk) as a potential target in ac

102 Integrin-based activation of spleen tyrosine kinase (Syk) contributes to myeloid cell

103 e used to compare WBNs to LDNs and delineate spleen tyrosine kinase (SYK) expression across neutrophi

104 l surface IgE and FceRI expression, cellular spleen tyrosine kinase (SYK) expression, IgE-mediated hi

105 Spleen tyrosine kinase (SYK) has an important role in im

106 Spleen tyrosine kinase (Syk) has been identified as an i

107 Spleen tyrosine kinase (Syk) has been implicated in a nu

108 Although spleen tyrosine kinase (SYK) has been implicated in hema

109 e sought to further evaluate the role of the spleen tyrosine kinase (Syk) in cGVHD in multiple murine

110 estigated the implication of FcgammaRIIa and spleen tyrosine kinase (Syk) in DC activation and showed

111 ssion of the intracellular signaling pathway spleen tyrosine kinase (Syk) in intestinal DCs from H. p

112 tagonizing the activities of RAF1, BRAF, and spleen tyrosine kinase (SYK) in normal B cells and CLL c

113 and colleagues describe the critical role of spleen tyrosine kinase (SYK) in paclitaxel resistance by

114 Inhibition of spleen tyrosine kinase (SYK) in tonic B-cell receptor (B

115 asari et al. find a role for the nonreceptor spleen tyrosine kinase (SYK) in upstream signaling leadi

116 Spleen tyrosine kinase (Syk) induces cell survival and p

117 ort to the development of clinical trials of spleen tyrosine kinase (Syk) inhibition for more effecti

118 1) antagonists, B-adrenergic agonists, and a spleen tyrosine kinase (Syk) inhibitor were best at indi

119 antagonists, beta-adrenergic agonists, and a spleen tyrosine kinase (Syk) inhibitor were best at indi

120 signaling pathway, PD98059 and U0126 and the spleen tyrosine kinase (Syk) inhibitor, Piceatannol.

121 by Siglec-1 was significantly attenuated by spleen tyrosine kinase (Syk) inhibitor.

122 n BMDCs from wild-type mice was inhibited by spleen tyrosine kinase (Syk) inhibitors and was abolishe

123 A novel approach to design selective spleen tyrosine kinase (Syk) inhibitors is described.

124 pment of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable d

125 Spleen tyrosine kinase (Syk) initiates and amplifies the

126 Spleen tyrosine kinase (Syk) is a candidate tumor (metas

127 Spleen tyrosine kinase (SYK) is a candidate tumor suppre

128 Spleen tyrosine kinase (SYK) is a critical immune signal

129 In this study, we report that spleen tyrosine kinase (Syk) is a critical regulator of

130 Spleen tyrosine kinase (Syk) is a cytoplasmic tyrosine k

131 Here we report that Spleen Tyrosine Kinase (Syk) is a key mediator of EC bar

132 The cytoplasmic spleen tyrosine kinase (SYK) is a key regulator of signa

133 Spleen tyrosine kinase (Syk) is a non-receptor tyrosine

134 Spleen tyrosine kinase (Syk) is a nonreceptor protein ty

135 Spleen tyrosine kinase (Syk) is a nonreceptor tyrosine k

136 Spleen tyrosine kinase (SYK) is a previously unidentifie

137 Spleen tyrosine kinase (Syk) is a protein tyrosine kinas

138 Spleen tyrosine kinase (SYK) is a signaling node in many

139 Spleen tyrosine kinase (Syk) is an attractive drug targe

140 Spleen tyrosine kinase (Syk) is an important modulator o

141 Spleen tyrosine kinase (Syk) is an intracellular nonrece

142 Spleen tyrosine kinase (SYK) is an intracellular protein

143 Spleen tyrosine kinase (Syk) is expressed in a variety o

144 Spleen tyrosine kinase (Syk) is important for Fc and B-c

145 Spleen tyrosine kinase (Syk) is involved in membrane-med

146 Spleen tyrosine kinase (Syk) is involved in the activati

147 Spleen tyrosine kinase (SYK) is predominantly expressed

148 Here we show that spleen tyrosine kinase (SYK) is upregulated during brown

149 ruitment in A. fumigatus phagosomes required spleen tyrosine kinase (Syk) kinase-dependent production

150 Spleen tyrosine kinase (Syk) mediates early signaling ev

151 oteins (total tyrosine phosphorylation), and spleen tyrosine kinase (Syk) phosphorylation after antig

152 ibits antigen-induced, FcepsilonRI-dependent spleen tyrosine kinase (Syk) phosphorylation and downstr

153 al numbers, exhibited unimpaired BCR-induced spleen tyrosine kinase (Syk) phosphorylation but reduced

154 The spleen tyrosine kinase (Syk) plays a central role in the

155 Spleen tyrosine kinase (SYK) plays a major role in infla

156 of Mule phosphorylation by silencing of the Spleen Tyrosine Kinase (Syk) prevents its dissociation f

157 Spleen tyrosine kinase (Syk) promotes leukocyte recruitm

158 Here we report that macrophage spleen tyrosine kinase (Syk) promotes PDAC growth and me

159 ctivation, as inhibition of the BCR-proximal spleen tyrosine kinase (SYK) reversed ERK hyperactivatio

160 xploring autoimmune diseases have shown that spleen tyrosine kinase (SYK) signalling is involved in t

161 We show that mmLDL induced recruitment of spleen tyrosine kinase (Syk) to a TLR4 signaling complex

162 1, a C-type lectin receptor that signals via spleen tyrosine kinase (Syk) to induce ROS.

163 rior to this, DENV immune complexes activate spleen tyrosine kinase (Syk) within 1 hpi.

164 The spleen tyrosine kinase (Syk), a key component of BCR sig

165 M), leading to recruitment and activation of spleen tyrosine kinase (Syk), a kinase that is essential

166 Spleen tyrosine kinase (Syk), a nonreceptor protein kina

167 In the present study, we concentrate on Spleen tyrosine kinase (Syk), a nonreceptor tyrosine kin

168 In this report, we assessed the role of spleen tyrosine kinase (SYK), a nonreceptor tyrosine kin

169 was applied to identify unique substrates of spleen tyrosine kinase (Syk), a protein-tyrosine kinase

170 Spleen tyrosine kinase (Syk), an immunoregulatory kinase

171 cellular signaling proteins FcepsilonRgamma, spleen tyrosine kinase (SYK), and EWS/FLI1-Activated Tra

172 Ks), DAP12 and Fc receptor-gamma (FcRgamma), spleen tyrosine kinase (Syk), and p38.

173 conjunction with Src family kinases (SFKs), spleen tyrosine kinase (Syk), and phospholipase gamma2 (

174 e, siRNA depletion of Mincle and its adaptor spleen tyrosine kinase (Syk), and Syk pharmacological in

175 IL-21 activated spleen tyrosine kinase (Syk), as evidenced by its abilit

176 ntral role of a nonreceptor tyrosine kinase, spleen tyrosine kinase (SYK), in mediating osteomyelitis

177 sphotyrosinylation and specifically recruits spleen tyrosine kinase (Syk), initiating cellular activa

178 dothelial selectins activate Src kinases and spleen tyrosine kinase (Syk), leading to alpha(L)beta(2)

179 tment of early signaling proteins, including spleen tyrosine kinase (Syk), linker for activation of T

180 arrow-derived macrophages exhibited elevated spleen tyrosine kinase (SYK), lysine methyltransferase 5

181 Inhibitors of sarcome (Src) tyrosine kinase, spleen tyrosine kinase (Syk), phosphoinositide 3-kinase

182 macrophages and dendritic cells deficient in spleen tyrosine kinase (Syk), we identified a novel path

183 ITAM) phosphorylation, and activation of the spleen tyrosine kinase (SYK), which initiates downstream

184 We identified spleen tyrosine kinase (Syk), which is activated by oxid

185 lipid-SH2 domain interaction inhibitors for spleen tyrosine kinase (Syk), which is implicated in hem

186 hematosus (SLE) display increased amounts of spleen tyrosine kinase (Syk), which is involved in the a

187 s phosphorylation induces the recruitment of spleen tyrosine kinase (Syk), which is required for down

188 Additionally, macrophages deficient in spleen tyrosine kinase (Syk), which signals downstream o

189 ell antigen receptor (BCR)-proximal effector spleen tyrosine kinase (SYK), which we identified as an

190 was TLR2-independent, involved sarcoma (SRC)-spleen tyrosine kinase (SYK)-Caspase recruitment domain-

191 e lectin member 5a (Clec5a), which encodes a spleen tyrosine kinase (SYK)-coupled surface receptor, a

192 up-regulated in GBM tissue samples through a spleen tyrosine kinase (SYK)-dependent activation of the

193 ymphoblastic leukemia (ALL) by targeting the spleen tyrosine kinase (SYK)-dependent antiapoptotic bla

194 erful platelet activation through a Src- and spleen tyrosine kinase (Syk)-dependent tyrosine phosphor

195 beta by fine-tuning pro-IL-1beta expression, spleen tyrosine kinase (SYK)-mediated NLRP3 activation a

196 ased on the activity of SHP1 phosphatase and spleen tyrosine kinase (Syk).

197 atosus (SLE) express increased levels of the spleen tyrosine kinase (Syk).

198 bl family kinases is mediated in part by the spleen tyrosine kinase (Syk).

199 ent on FcgammaR signaling events mediated by spleen tyrosine kinase (Syk).

200 a novel association of CD36 with VEGFR-2 and spleen tyrosine kinase (Syk).

201 -competitive inhibitor of the BCR-associated spleen tyrosine kinase (SYK).

202 on-associated antigen-1 by signaling through spleen tyrosine kinase (Syk).

203 rolling on P-selectin, and to signal through spleen tyrosine kinase (Syk).

204 eraction with TLR2 or by directly activating spleen tyrosine kinase (Syk).

205 novel target for curcumin in B lymphoma viz spleen tyrosine kinase (Syk).

206 athways by counteracting the cell-activating spleen tyrosine kinase (Syk).

207 e the inhibition of critical kinases such as spleen tyrosine kinase (Syk).

208 s allowing for the binding and activation of spleen tyrosine kinase (Syk).

209 ntly downregulated gene in both datasets was spleen tyrosine kinase (SYK).

210 rc homology phosphatase-1 to dephosphorylate spleen tyrosine kinase (Syk).

211 ine revealed that this compound inhibits the spleen tyrosine kinase (Syk).

212 llular redistribution with F-actin by way of spleen tyrosine kinase (SYK).

213 ed by the equilibrium between kinases (e.g., spleen tyrosine kinase [Syk]) and phosphatases (e.g., Sh

214 META060 inhibited the activity of kinases (spleen tyrosine kinase [Syk], Bruton's tyrosine kinase [

215 signaling nodes (Src family tyrosine kinase, spleen tyrosine kinase [SYK], phospholipase Cgamma), but

216 Because spleen tyrosine kinase, Syk, is an upstream kinase in mu

217 contrast, levels of IgE receptor-associated spleen tyrosine kinase, Syk, were increased on day 4 (P

218 tream of CD18 integrins are dependent on the spleen tyrosine kinase, Syk.

219 or macrophages treated with an inhibitor of spleen tyrosine kinase, the tyrosine kinase that signals

220 n the involvement of protein tyrosine kinase spleen tyrosine kinase, they point to the role of recept